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We investigated whether intra-arterial administration of carboplatin using Calvert’s formula is useful for avoiding thrombocytopenia in
targeted chemoradiotherapy in patients with squamous cell cancer of the oral cavity and oropharynx. Carboplatin was infused intra-
arterially under digital subtraction angiography in 28 patients. In the first group of patients, the dose of carboplatin was calculated
according to the body surface area (BS group). In the second group, the dose was calculated using Calvert’s formula (AUC group).
The value for AUC (area under concentration vs time curve; mgml
 1min
 1) in the formula was set at 4.5. All patients received
concurrent radiotherapy (30Gy) and were given oral tegafur-uracil (UFT
s, 400–600mgday
 1). The AUC group showed a
significantly lower percentage platelet reduction than the BS group (49.0722.0 vs 65.1723.2%; P¼0.045) and also tended to have a
higher platelet nadir count (10.974.2 vs 8.475.8 10
4; P¼0.27) without reducing the antitumour effect. The value of 4.5 for target
AUC is recommended clinically. However, AUC of Calvert’s formula could not predict thrombocytopenia associated with intra-
arterial chemoradiotherapy due to the variability of the actual AUC.
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Concurrent intravenous systemic chemotherapy and radiation
therapy has been applied to locally advanced squamous cell cancer
of the oral cavity and oropharynx (Mohr et al, 1994). Several
studies have been published using chemoradiotherapy based on
intravenous platinum derivatives for advanced head and neck
cancer, as a strategy for preoperative treatment or organ pre-
servation (Koch et al, 1995; Kirita et al, 1996; Wanebo et al, 1997).
Recent advances in the angiographic technique have enabled
intra-arterial administration of chemotherapeutic agents under
fluoroscopic guidance directly through microcatheters to selec-
tively saturate the targeted primary tumour (Robbins et al, 1992;
Imai et al, 1995; Korogi et al, 1995). Encouraging results, including
high tumour response rates and good local and regional control,
have been noted with targeted intra-arterial chemotherapy and
concomitant radiation therapy for advanced head and neck cancer
(Robbins et al, 1997; Oya and Ikemura, 1999).
Carboplatin has been commonly used as one of the chemother-
apeutic agents for patients with squamous cell carcinoma of the
oral cavity and oropharynx, either in neo-adjuvant chemotherapy
or in combination with radiation therapy (Aisner et al, 1992;
Wanebo et al, 1997). Myelosuppression, associated especially with
thrombocytopenia, is a major dose-limiting factor in this type of
therapy. In order to avoid severe thrombocytopenia, Calvert’s
formula has been reported as being useful for calculating the
intravenously injected dose of carboplatin (Calvert et al, 1989).
However, it remains uncertain whether a dose for intra-arterial
administration determined by Calvert’s formula would also be
effective in predicting the occurrence of thrombocytopenia.
Calvert’s formula consists of the area under the blood concentra-
tion–time curve (AUC) and patient’s renal function. It is unclear
as to what value for AUC is appropriate in the formula for intra-
arterial administration.
The aim of this study is to investigate the usefulness of Calvert’s
formula in targeted intra-arterial administration of carboplatin
and concurrent radiotherapy, in combination with oral adminis-
tration of tegafur-uracil (UFT
s) (Carmichael et al, 2002) to avoid
thrombocytopenia and to achieve good treatment response in
patients with squamous cell cancer of the oral cavity and
oropharynx. Further, we determined an actual value for the AUC
of plasma-free platinum by serial sampling from the patients, and
the result was compared with the target AUC.
MATERIALS AND METHODS
A total of 15 patients with histologically proven squamous cell
cancer of the oral cavity and oropharynx were treated by targeted
intra-arterial administration of carboplatin and concurrent radio-
therapy in combination with oral UFT
s at our university hospital
between April 1995 and April 1997. Carboplatin dose was
calculated according to the patient’s body surface area (BS group),
with the amount of carboplatin (mg) being set at 350 body
surface area (m
2). In 13 patients treated between May 1997 and
August 1998, the dose was calculated using Calvert’s formula, with
24-h creatinine clearance (Ccr) being used as a substitute for the
glomerular filtration ratio (GFR). As carboplatin is mainly excreted
from the kidneys, we considered it appropriate to take into
account the patient’s renal function when determining the dose,
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land to expect this change to contribute to the avoidance of
thrombocytopenia. In Japan, 24-h Ccr (mlmin
 1) is often
substituted for GFR. In order to evaluate the differences between
individuals, GFR was compensated using the standard body
surface area of Japanese, 1.48m
2, and was estimated as 24-h
Ccr patient’s body surface area/1.48. Based on the formula, the
amount of carboplatin (mg) was set at AUC  (GFRþ25) (Calvert
et al, 1989). The figure for target AUC in the formula was set as
4.5mgml
 1min
 1, considering the combined use of radiotherapy
and UFT
s (AUC group). Characteristics of the two patient groups
are summarised in Table 1. TNM stage of the tumour was classified
in accordance with the UICC system published in 1987 (Hermanek
and Sobin, 1987). During this study, except for the dose-setting
methods for carboplatin, we did not change any clinical practice to
influence outcomes between the two treatment groups. This study
is a retrospective review of clinical practice offered to the patients.
Written informed consent was obtained from all patients
concerning treatment choice for their tumour.
Intra-arterial carboplatin infusion was carried out through a
microcatheter positioned angiographically, targeting only the
dominant blood supply of the primary tumour. The injection
was performed using an infusion pump, and the rate of infusion
was fixed at 150mlh
 1. At the end of the carboplatin infusion,
intra-arterial methyl prednisolone (125mg) was administered to
prevent intimal damage of the artery containing the microcatheter.
Arterial catheterisation was performed by the interventional
radiologist, and the catheter was removed following the infusion.
Radiation therapy consisted of either conventional external beam
X-ray radiation (1.8–2.0Gy per fraction; two patients) or
accelerated hyper fractionation radiation (1.5Gy per fraction;
twice daily; 26 patients). The tumour was radiated with a total dose
of 30Gy. Intra-arterial infusion was administered after an
irradiation of about 10Gy. Tegafur-uracil (UFT
s, 400–
600mgday
 1) was administered orally from the time of perform-
ing the diagnostic biopsy to completion of radiotherapy.
Pharmacokinetic sampling for free platinum concentration in
the plasma was performed on 12 patients in the AUC group. Blood
samples (5ml) were collected in tubes immediately after carbo-
platin injection and then at 30min, 1h, 2h, 6h, and 24h. Each
sample was centrifuged at 3000rpm for 10min. Plasma was then
placed in an ultrafiltration kit (Centrifree MPS-3; Amicon Inc.,
Tokyo) and was centrifuged for 15min at 3000rpm. This plasma
ultrafiltrate was immediately frozen and stored at  201C. Platinum
was determined by flameless atomic absorption spectrophotome-
try. The AUC of free platinum was calculated using the trapezoidal
rule from the concentration–time curve of free platinum in the
ultrafiltrate.
The degree of thrombocytopenia was assessed by World Health
Organization (WHO) toxicity criteria, platelet nadir count, and the
percentage reduction in platelet count. The percentage reduction
in platelet count was calculated as [(pretreatment count nadir
count)/pretreatment count] 100.
After completion of radiotherapy with a single carboplatin
infusion, all patients underwent an evaluation to determine the
degree of side effects and the clinical response of the tumour
including CT and MRI studies. Response criteria were defined as
follows: complete response (CR), complete disappearance of the
tumour mass; partial response (PR), shrinkage of the tumour mass
greater than 50% of the product of the perpendicular diameters; no
change (NC), shrinkage of less than partial response.
Differences between the two groups were compared using the
Mann–Whitney U-test for univariate nonparametric statistical
analysis. Spearman correlation coefficients were used to examine
the relationship between the percentage reduction, nadir count in
platelet and AUC, Ccr, and total dose of administered carboplatin.
Data were considered statistically significant if P-values were less
than 0.05.
RESULTS
All selected arteries for injection were branches of the external
carotid artery, and the mean number of injected arteries was 2.1
vessels per tumour in the BS group, and 1.9 vessels in the AUC
group. A total of time of intra-arterial injection to the tumour
ranged from 18 to 69min (mean 35715min, median 32min) in
the BS group, and from 13 to 63min (mean 26714min, median
21min) in the AUC group. The BS group had significantly longer
time for injection than the AUC group (P¼0.04). The total dose of
administrated carboplatin was higher in the BS group than in the
AUC group. The BS group showed more locally advanced primary
tumours than the AUC group (Table 1).
The relationship between the administered dose of carboplatin
and the degree of thrombocytopenia in the BS group is shown in
Figure 1. A weak linear relationship was observed between the
carboplatin dose and the platelet nadir count (r¼0.57; P¼0.04),
and between the dose and the percentage platelet reduction
(r¼0.53; P¼0.04); however, these results do not imply a
meaningful correlation, that is, with the increase of the carboplatin
dose, the reduction rate decreased and the nadir increased. In 13
patients of the BS group, in whom the pretreatment 24-h Ccr
values were known, the figure of Ccr was correlated to the degree
of thrombocytopenia. There were no relationships between the Ccr
and the platelet nadir count (r¼0.25; P¼0.38), or between the
Ccr and the percentage platelet reduction (r¼-0.32; P¼0.26), as
described in Figure 2. However, severe thrombocytopenia (the
WHO grade 4) was recognised in two of 15 patients (Table 1), and
both the two patients revealed a decreased figure of Ccr (63.1,
71.6ml
 1min
 1, respectively).
Table 1 Patient characteristics and degree of thrombocytopaenia in two
different carboplatin dose determination groups, for 28 patients with
cancer of the oral cavity and oropharynx
Variables
BS group
(n¼15)
AUC group
(n¼13) P-value
Gender 0.29
Male 12 8
Female 3 5
Age (years) 55–80 43–80 0.42
T stage 0.01
T2 1 8
T3 2 0
T4 12 3
rT3 0 1
rT4 0 1
Creatinine clearance (mlmin
 1) 90.2720.5 90.6720.0 0.94
Injected dose of carboplatin
(mgbody
 1)
542767 4887107 0.055
Response of the primary tumour 0.85
CR 9 8
PR 4 5
NA 2 0
WHO thrombocytopaenia grade 0.7
06 7
13 3
22 1
32 2
42 0
BS¼body surface area, AUC¼area under concentration–time curve, Plt¼platelet,
NA¼not assessed, T stage is in accordance with the UICC system in 1987.
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lFigure 3 shows the time curves of plasma ultrafiltrate free
platinum concentration (mean7s.d.) in the 12 patients injected
with carboplatin, based on a target AUC value of 4.5. The actual
AUC of free platinum was found to be 6.571.0mgml
 1min.
Figure 4 shows the relationship between the actual AUC and the
degree of thrombocytopenia. There was no correlation between the
actual AUC and the platelet nadir count (r¼0.15; P¼0.63), or
between the actual AUC and the percentage platelet reduction
(r¼ 0.14; P¼0.63).
The percentage reduction in platelet count revealed a signifi-
cantly lower value in the AUC group than that in the BS group
(P¼0.045). In addition, the AUC group had no occurrence of
grade 4 thrombocytopenia, and exhibited a greater nadir count
than the BS group (Figure 5). Otherwise, there were no significant
differences between the two groups with respect to the WHO
thrombocytopenia grade (P¼0.70), injected carboplatin dose, and
in patient’s renal function (24-h Ccr).
A clinical response to the therapy in 26 patients revealed 17 CR
(65%) and nine PR (35%). There was no difference in response
between the two groups. Two patients in the BS group had not
completed planned radiation therapy because they developed
severe myelosuppression (leukopenia and thrombocytopenia), and
were excluded from the evaluation of clinical response (Table 1).
DISCUSSION
We have already reported a good clinical and histological result
using intra-arterial carboplatin chemoradiotherapy, in which the
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Figure 2 Platelet nadir count (A), percentage platelet reduction (B) and
creatinine clearance in the13 patients injected with 350mgm
 2 of
carboplatin (BS group).
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Figure 3 Plasma profile of free platinum in the 12 patients injected with
carboplatin with the target AUC set at 4.5mgml
 1min
 1 (AUC group).
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Figure 1 Platelet nadir count (A), percentage platelet reduction (B) and
total dose of carboplatin in the 15 patients injected with 350mgm
 2 of
carboplatin (BS group).
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ldose was determined according to the patient’s body surface area
(Oya and Ikemura, 1999). However, unpredicted severe thrombo-
cytopenia and leukocytopenia developed in three of 15 patients
with squamous cell cancer of the oral cavity and oropharynx, and
two of these three patients could not complete planned therapy
due to secondary complications following myelosuppression (one
with sepsis, the other with DIC). Thus, our experience indicated
the need for appropriate intra-arterial dose determination of
carboplatin.
The major dose-limiting factor for carboplatin therapy has been
recognised to be thrombocytopenia. When carboplatin is admini-
strated preoperatively (as in neo-adjuvant or induction che-
motherapy), it is essential to predict the development of
thrombocytopenia for the successful performance of the planned
surgery. In order to avoid severe thrombocytopenia, it has been
reported that it is useful to calculate the intravenously injected
dose of carboplatin using Calvert’s formula, according to both
AUC and the renal function of the individual patient. Calvert et al
(1989) reported that the AUC value is the most important factor in
determining the degree of thrombocytopenia and myelosuppres-
sion that can be expected in response to a dose of carboplatin. In
the administration of carboplatin, either as a single agent or in
combination with other drugs, the AUC value has been reported in
many cancers to predict the degree of myelosuppression.
UFT also has haematological toxicity (neutropenia, thrombocy-
topenia). In a previous study in which UFT was used as a single
chemotherapy agent for treating colorectal cancer, thrombocyto-
penia was observed in 18% of cases (33 out of 187) and graded as
severe in only one case (Carmichael et al, 2002). In the
thrombocytopenia observed in our intra-arterial chemoradiother-
apy, UFT might have influenced its occurrence and its severity.
UFT may also have been directly responsible for the thrombocy-
topenia; however, we could not evaluate the degree of its
contribution to the thrombocytopenia.
Calvert’s formula has been shown to be effective for intravenous
administration, but its usefulness for intra-arterial injection has
remained unknown. We have found no previous reports on the
usefulness of AUC for intra-arterial infusion of carboplatin. The
degree of thrombocytopenia in the BS group was not associated
with the administrated dose of carboplatin (Figure 1). In addition,
severe thrombocytopenia (the WHO grade 4) was recognised in
two of 15 patients (Table 1), and the two patients showed
decreased value of Ccr. These results suggest that the calculated
dose of carboplatin according to the patient’s body surface area is
inappropriate to predict the development of thrombocytopenia,
and a dose should be considered with a patient’s renal function.
The thrombocytopenia in the AUC group showed no association
with the actual AUC (Figure 4). These results suggest that the
actual AUC value itself in Calvert’s formula for the intra-arterial
administration of carboplatin could not predict thrombocytopenia
due to the variability of the actual AUC. However, the percentage
reduction in platelet count revealed a significantly lower value in
the AUC group than that in the BS group (P¼0.045) (Figure 5).
This means that an individual dose strategy based on renal
function helps to avoid the thrombocytopenia associated with
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Figure 5 Difference of platelet nadir count (A) and percentage platelet
reduction (B) between the BS and AUC groups.
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actual AUC in the 12 patients injected with carboplatin with the target
AUC set at 4.5mgml
 1min
 1 (AUC group).
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lintra-arterial chemoradiotherapy in patients with cancer of the
oral cavity and oropharynx.
When determining the appropriate dose of carboplatin, the
value set for the target AUC and the precise measurement of GFR
are crucial, with respect to both the chemotherapeutic effect and
the reduction of myelosuppression. Calvert et al proposed that an
AUC value of no less than 4mgml
 1min
 1, and preferably as high
as 5mgml
 1min
 1, should be used for intravenous carboplatin
when administered in combination with other cytotoxic agents.
Setting our target AUC value at 4.5mgml
 1min
 1 was therefore
considered to be appropriate for the combination of intra-arterial
carboplatin, oral UFT, and radiotherapy. This value was supported
by the finding that the incidence of thrombocytopenia was reduced
without a decrease in the response of the primary tumour, when
comparing the BS and AUC groups (Table 1). If the target AUC
value is at higher than 4.5mgml
 1min
 1, the total injected dose of
carboplatin increases and the severity of thrombocytopenia is
expected to be worse. We could not predict the difference between
the total injected doses of carboplatin between the two groups.
From our results for thrombocytopenia and treatment response of
the tumours, the value of 4.5 for the target AUC is considered to be
appropriate and is recommended for clinical practice. In all, 20
patients with squamous cell carcinoma of the oral cavity and
oropharynx have been treated according to the same treatment
regimen as the AUC group from September 1998. The results
revealed no occurrence of severe thrombocytopenia (WHO grade
4) and good clinical and histological complete response rates (89
and 71%, respectively). From these encouraging results, our
targeted intra-arterial chemoradiotherapy could be applied as a
strategy for organ preservation or less invasive surgery with
acceptable haematological toxicity.
In our pharmacokinetic study, the actual AUC was generally
higher than the target AUC. Among the various factors accounting
for differences between the actual and target AUC, both
carboplatin clearances within the tumour tissue and the time to
complete the intra-arterial administration may be important. As a
drug is delivered directly to the tumour tissue in target intra-
arterial chemotherapy, carboplatin clearance is expected to be
influenced largely either by the tumour/normal tissue blood flow
ratio, or from the degree of vascularity within the tumour. In order
to completely saturate a tumour tissue, multiple arteries must be
selected for infusion. This requires time to exchange the
microcatheter, and leads to an intermittent administration of
carboplatin. In contrast to continuous intravenous infusion, this
intermittent administration could account for the difference
between the actual and the target AUC value in our intra-arterial
chemotherapy.
ACKNOWLEDGEMENTS
We appreciate Nobuhiro Onari, MD, PhD, in the Department of
Radiology, University of Occupational and Environmental Health,
for his performance of intra-arterial catheterisation and angio-
graphy, and also thank Bristol-Myers Squibb KK for the
measurement of the free platinum concentration and the evalua-
tion of the concentration–time curve of ultrafiltrate free platinum.
REFERENCES
Aisner J, Sinibaldi V, Eisenberger M (1992) Carboplatin in the treatment of
squamous cell head and neck cancers. Sem Oncol 19: 60–65
Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE,
Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage:
prospective evaluation of a simple formula based on renal function. J
Clin Oncol 7: 1748–1756
Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard
T, Munier S, Martin C (2002) Randomized comparative study of tegafur/
uracil and oral leucovorin versus parenteral fluorouracil and leucovorin
in patients with previously untreated metastatic colorectal cancer. J Clin
Oncol 20: 3617–3627
Hermanek P, Sobin LH (1987) TNM Classification of Malignant Tumours.
Berlin: Springer-Verlag 16pp
Imai S, Kajihara Y, Munemori O, Kamei T, Mori T, Handa T, Akisada K,
Orita Y (1995) Superselective cisplatin (CDDP)–carboplatin (CBDCA)
combined infusion for head and neck cancers. Eur J Radiol 21: 94–99
Kirita T, Ohgi K, Tsuyuki M, Kamikaido N, Yamamoto K, Sugimura M
(1996) Preoperative simultaneous cisplatin- or carboplatin-based che-
motherapy and radiotherapy for squamous cell carcinoma of the oral
cavity. J Surg Oncol 63: 240–248
Koch WM, Lee DJ, Eisele DW, Miller D, Poole M, Cummings CW,
Forastiere A (1995) Chemoradiotherapy for organ preservation in
oral and pharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 121:
974–980
Korogi Y, Hirai T, Nishimura R, Hamatake S, Sakamoto Y, Murakami R,
Baba Y, Takahashi M, Uji Y, Taen A (1995) Superselective intraarterial
infusion of cisplatin for squamous cell carcinoma of the mouth:
preliminary clinical experience. AJR 165: 1269–1272
Mohr C, Bohndorf W, Carstens J, Harle F, Hausamen JE, Hirche H,
Kimmig H, Kutzner J, Muhling J, Reuther J (1994) Preoperative
radiochemotherapy and radical surgery in comparison with radical
surgery alone. A prospective, multicentric, randomized DOSAK
study of advanced squamous cell carcinoma of the oral cavity and
the oropharynx (a 3-year follow-up). Int J Oral Maxillofac Surg 23:
140–148
Oya R, Ikemura K (1999) Targeted intra-arterial carboplatin infusion
with concurrent radiotherapy and administration of tegafur for advanced
squamous cell carcinoma of the oral cavity and oropharynx. In
Intra-arterial Chemotherapy in Head and Neck Cancer – Current Results
and Future Perspectives, Eckardt A (ed) pp 183–190 Reinbek: Einhorn-
Press Verlag
Robbins KT, Kumar P, Regine WF, Wong FS, Weir AR, Flick P, Kun LE,
Palmer R, Murry T, Fontanesi J, Ferguson R, Thomas R, Hartsell W, Paig
CU, Salazar G, Norfleet L, Hanchett CB, Harrington V, Niell HB (1997)
Efficacy of targeted supradose cisplatin and concomitant radiation
therapy for advanced head and neck cancer: the Memphis experience. Int
J Radiat Oncol Biol Phys 38: 263–271
Robbins KT, Storniolo AM, Kerber C, Seagren S, Berson A,
Howell SB (1992) Rapid superselective high-dose cisplatin
infusion for advanced head and neck malignancies. Head Neck 14:
364–371
Wanebo HJ, Chougule P, Akerley WR, Koness RJ, McRae R, Nigri P, Leone
L, Ready N, Safran H, Webber B, Cole B (1997) Preoperative
chemoradiation coupled with aggressive resection as needed ensures
near total control in advanced head and neck cancer. Am J Surg 174:
518–522
AUC in targeted carboplatin chemoradiotherapy
R Oya et al
2066
British Journal of Cancer (2004) 90(11), 2062–2066 & 2004 Cancer Research UK
C
l
i
n
i
c
a
l